骨质疏松症治疗新进展：从机制探索到临床实践

蔡 熹, 朱 忠祥
武汉市普仁医院

摘要


骨质疏松症是一种以骨量减少、骨微结构破坏为特征的全身性骨骼疾病，使骨折风险增加。由于骨质疏松症患者群体中存在人口老龄化问题，因此对骨质疏松症的防治已经引起了全世界的高度重视。本文针对骨质疏松症的发病机制、传统药物的优化、新型靶向药物、生物制剂以及联合治疗、个体化治疗等内容展开综述。虽然近年来出现诸多针对骨质疏松症的有效治疗方法，但仍然存在安全性、远期疗效、顺应性等问题有待解决，未来研究应围绕精准治疗及新药临床应用转化方向开展。

关键词


骨质疏松症；骨代谢；靶向治疗；生物制剂；联合治疗；个体化治疗

全文:

PDF


参考


[1]Cai R,Jiang Y,Sun H,et al.Advances in Functionalized Nanoparticles for Osteoporosis Treatment.Int J Nanomedicine.20:7869-7891.

[2]Zhang X,Liang Y,Zhang F,Liu X. Osteoporosis: molecular pathogenesis and therapeutic interventions.Mol Biomed. 2025;6(1):98.

[3]Aditya S,Rattan A.Sclerostin Inhibition:A Novel Target for the Treatment of Postmenopausal Osteoporosis.J Midlife Health.2021 Oct-Dec;12(4):267-275.

[4]Liu C,Zhang J,Ye Z, Luo J, Peng B,Wang Z. Research on the role and mechanism of the PI3K/Akt/mTOR signalling pathway in osteoporosis. Front Endocrinol(Lausanne).16:1541714.

[5]Liu C,Yang J,Dong Z,et al.The central mechanotransducer in osteoporosis pathogenesis and therapy.Front Endocrinol(Lausanne). 16:1658967.

[6]Jin H,Dong Y,Huang C,et al.Comparative efficacy and safety of teriparatide versus bisphosphonates in osteoporosis:a meta-analysis. Front Surg.12:1582180.

[7]Zhang N,Zhang ZK,Yu Y,Zhuo Z,Zhang G, Zhang BT.Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy.Front Cell Dev Biol.8:325.

[8]Lim SY.Romosozumab for the treatment of osteoporosis in women:Efficacy,safety,and cardiovascular risk.Womens Health(Lond). 18:17455057221125577.

[9]He Y,Liao T,Wang X,et al.Application of proteolysis targeting chimeric(PROTAC) technology in protein regulation and drug development.Bioorg Chem.164:108846.


Refbacks

  • 当前没有refback。